The Cannabis Use Disorder market is witnessing rapid expansion driven by increasing awareness of substance abuse challenges and the rising adoption of therapeutic interventions. Industry stakeholders are focusing on innovative treatment modalities and expanding their product portfolios to address unmet clinical needs effectively.
Market Size and Overview
The cannabis use disorder market is estimated to be valued at USD 1.80 Bn in 2025 and is expected to reach USD 3.40 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.5% from 2025 to 2032.
This steady Cannabis Use Disorder Market growth is propelled by rising investment in drug development, favorable regulatory policies, and enhanced diagnostic capabilities. The market report highlights evolving market dynamics centered on innovation and increasing healthcare infrastructure across developed and emerging regions.
Market Segments
The market is segmented primarily by product type, treatment approach, and end-user category.
- By Product Type: The key categories include medication therapies, behavioral therapies, and combination treatments. Among these, medication therapies dominate due to proven efficacy, while combination therapies are the fastest-growing segment, witnessing a 12% revenue uptick in 2024 supported by recent clinical trial successes.
- By Treatment Approach: Segments include pharmacological interventions and psychosocial support. Pharmacological approaches hold a significant market position, driven by new drugs targeting cannabinoid receptors. Psychosocial support shows promising growth due to personalized care demand.
- By End-User: Hospitals, outpatient clinics, and rehabilitation centers are the main end users. Outpatient clinics are the fastest growing segment, buoyed by an increase in ambulatory care services and accessibility improvements observed in 2025.
Market Drivers
One of the principal market drivers is the increased implementation of supportive government policies worldwide. In 2024, regulatory bodies in North America and Europe approved enhanced reimbursement frameworks for therapies treating cannabis use disorder, which directly accelerated market growth. Furthermore, 2025 data show a 15% rise in clinical trial activity focusing on cannabinoid receptor modulators, underpinning robust innovation that fuels market opportunities. This regulatory endorsement and product-level advancement are pivotal market revenue catalysts.
Segment Analysis: Product Type
Focusing on the product type segment, medication therapies accounted for the highest market revenue in 2024, driven largely by drugs developed by major players such as Pfizer and Indivior. These therapies are preferred due to targeted efficacy and better patient compliance. Conversely, combination treatments—integrating both pharmacological and behavioral methods—registered the fastest growth rate of 12% in 2024, backed by clinical case studies demonstrating improved long-term abstinence rates. This dual approach is predicted to significantly influence business growth within this segment through 2032.
Consumer Behaviour Insights
Recent behavioral studies indicate three critical trends among patients and healthcare providers managing cannabis use disorder. Firstly, there is a marked shift towards digital health platforms; telemedicine utilization in treatment protocols increased by 20% in 2024 alone, reflecting greater preference for remote consultations. Secondly, pricing sensitivity is influencing therapy selection, as 65% of surveyed patients in 2025 indicated preference for cost-effective treatment plans without compromising quality.
Lastly, sustainability in treatment delivery is becoming a priority, with 40% of providers adopting eco-friendly packaging and supply chain measures, aligning with broader healthcare sector trends. These market trends surface vital consumer preferences shaping future market scope.
Key Players
Prominent market players shaping the Cannabis Use Disorder landscape include Aelis Farma, Indivior, Pfizer, Corbus Pharmaceuticals, and Zynerba Pharmaceuticals. In 2024-2025, these market companies launched novel therapies and expanded production capacities, driving robust market momentum.
For instance, Pfizer’s 2025 capacity expansion in biopharmaceutical manufacturing facilitated faster product rollout, enhancing market penetration. Meanwhile, Indivior ventured into new regional markets across Asia-Pacific, widening its global footprint. Such strategic actions have amplified the overall Cannabis Use Disorder market size and revenue.
Key Winning Strategies Adopted by Key Players
Several impactful strategies stand out for their contribution to business growth in 2024–2025:
- Innovative Drug Reformulation: Zynerba Pharmaceuticals re-engineered its cannabinoid-based therapy in 2025, improving bioavailability. This led to a 25% increase in patient adherence, a strategy not widely adopted but significantly effective in enhancing treatment outcomes.
- Digital Therapeutics Integration: Indivior pioneered integration of digital therapeutics with traditional medication in 2024, launching a connected health app alongside its pharmaceutical offerings. This innovation improved patient engagement and data collection, offering competitors a model for market growth strategies.
- Strategic Collaborations: Corbus Pharmaceuticals formed collaborations with regional rehabilitation centers in 2025 to co-develop personalized treatment protocols, a unique market opportunity approach that strengthened its presence in niche markets.
These strategies emphasize innovation beyond conventional approaches, providing valuable insights for market participants eyeing competitive advantage.
FAQs
1. Who are the dominant players in the Cannabis Use Disorder market?
Key market players include Aelis Farma, Indivior, Pfizer, Corbus Pharmaceuticals, and Zynerba Pharmaceuticals, all actively expanding product portfolios and geographic reach in 2024-2025.
2. What will be the size of the Cannabis Use Disorder market in the coming years?
The market size is projected to grow from USD 1.80 billion in 2025 to USD 3.40 billion by 2032, representing a CAGR of 10% driven by innovation and regulatory support.
3. Which treatment segment holds the largest growth opportunity?
Combination therapies integrating pharmacological and behavioral interventions show the fastest growth, with a 12% revenue increase noted in 2024, pointing to significant opportunities for tailored treatment approaches.
4. How will market development trends evolve over the next five years?
Market trends indicate rising adoption of digital health platforms, enhanced regulatory reimbursement, and growing consumer preference for sustainable treatment delivery, which will dynamically shape market growth.
5. What is the nature of the competitive landscape and challenges in the Cannabis Use Disorder market?
The competitive landscape is marked by innovation-focused market players addressing stringent regulatory environments and cost pressures, balancing rapid product development with access and affordability.
6. What go-to-market strategies are commonly adopted in the Cannabis Use Disorder market?
Successful strategies include drug reformulation for enhanced efficacy, integration of digital therapeutics with conventional treatments, and strategic collaborations with healthcare providers to tailor therapies and expand regional presence.
‣ Get more insights on : Cannabis Use Disorder Market
‣ Get this Report in Japanese Language : 大麻使用障害市場
‣ Get this Report in Korean Language : 대마사용장애시장
‣ Read More Related Articles : Global EYLEA Drug - A Breakthrough In Treatment Of Retinal Diseases
Author Bio:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )
Comments
0 comment